Core Insights - Enwei Pharmaceutical reported a significant increase in revenue and net profit for the first half of the year, with total revenue reaching 449 million yuan, a year-on-year increase of 15.73%, and net profit attributable to shareholders reaching 38.34 million yuan, a substantial growth of 113.8% [1][2] Group 1: Financial Performance - The company's revenue from its main product, "Jieryin Wash," continues to dominate the gynecological traditional Chinese medicine market, maintaining the largest market share since 2025, indicating strong brand recognition and influence [1] - Despite facing significant cost pressures, the gross margin for the gynecological segment remained high at 58.31%, with double-digit revenue growth year-on-year, showcasing strong pricing power and market control [1] Group 2: Business Expansion and R&D - Other business segments showed remarkable growth, with revenue increasing by 48.78% and a gross margin of 45.69%, becoming a new driving force for the company's overall growth [2] - The company maintains a high level of investment in R&D, focusing on the consistency evaluation of related drugs and advancing products towards high quality and standards, enhancing market recognition [2] - Enwei Pharmaceutical currently holds 21 exclusive products, demonstrating strong product differentiation capabilities [2] Group 3: Future Outlook - The company is poised to benefit from the high-quality development policies in the traditional Chinese medicine industry and the growing demand driven by the "Healthy China" initiative, presenting new development opportunities [2]